Introduction
An update of the German S3 guidelines on long-term opioid therapy of chronic noncancer pain (CNCP), the"LONTS" (Langzeitanwendung von Opioiden bei nicht tumorbedingten Schmerzen; AWMF registration number 145/003), was required as the validity of the first version of the guidelines expired in May 2014.
Objective of the guidelines
The guidelines are an aid to orientation for treatment providers and patients with CNCP regarding the potential harms and benefits associated with opioid-containing analgesics. The guidelines provide physicians with concrete recommendations for identifying indications, as well as for administering and terminating a therapy using opioid-containing analgesics. In accordance with the criteria of evidence-based medicine, the recommendations correspond to the most up-to-date scientific knowledge (best currently available evidence) and experiences in clinical practice. These guidelines aim to fulfill the following disease-specific goals:
Structural quality. The recommendations on contraindications, possible indications, administration and termination of a therapy with opioid-containing analgesics should reduce the problems associated with transfer of patients between the outpatient, inpatient and rehabilitation sectors, as well as the problems arising between general practitioners and specialist physicians.
Procedural quality. (1) The guidelines name measures to provide patients with CNCP with appropriate information on a therapy with opioid-containing analgesics. ( 2) The guideline recommendations represent practical tools for the administration and documentation of a therapy with opioid-containing analgesics. (3) The guidelines provide physicians with concrete instructions on how to deal with problems encountered during therapy of CNCP with opioid-congaing analgesics.
Quality of results.
(1) The guidelines should promote realistic therapeutic goals and appropriate behavior (e.g. whilst driving) from persons undergoing treatment with opioid-containing analgesics. (2) The inappropriate treatment of patients with fibromyalgia syndrome and somatoform pain disorders with opioid-containing analgesics should be reduced. ( 3) The number of patients misusing prescription opioid-containing analgesics should be reduced. (4) Patient safety should be improved. ist area; physicians without specific specialization), 1 specialist physician sector (all areas of medicine concerned with patients); F treatment-supporting professions (e.g. pharmacy, occupational therapy, physiotherapy, social work/social pedagogy/sociotherapy);
F relatives of persons with CNCP; F decision makers in the health care sector; F the public, to provide information on good diagnostic and therapeutic approaches; F those responsible for"structured treatment programs" and"integrated care" contracts; F specialist medical scientific societies and other publishers of national and international guidelines.
Methods

Members of the guideline committee
Steering committee
On 21.06.2013, the executive committee of the Deutsche Schmerzgesellschaft decided to update the interdisciplinary S3 guidelines on long-term opioid therapy of chronic noncancer pain CNCP, the"LONTS" (Langzeitanwendung von Opioiden bei nicht tumorbedingten Schmerzen; AWMF registration number 041/003 [23] ). During a meeting of the steering committee responsible for the first version of the guidelines on 24.10.2013 at the German Pain Congress, PD Dr. med. Winfried Häuser was elected to steering committee spokesman. PD Dr. med. Winfried Häuser was appointed the task of performing the literature search and producing the evidence report.
The executive committee of the Deutsche Schmerzgesellschaft nominated 17 society members to comprise the steering committee. Criteria for the selection were clinical and/or scientific expertise in the therapy of patients with CNCP, as well as the best-possible balance of representation by the different areas of medicine which treat patients with CNCP particularly frequently (anesthetics, internal medicine, neurology, orthopedics, psychosomatic medicine), clinical psychology, and subject-relevant subbranches and additional categorizations, such as geriatrics and palliative medicine. Prof. Dr. med. Stein, Berlin, stepped down from the steering committee because he did not agree with the methodology of the update of the guideline recommen-dations. PD Dr. med. Matthias Schuler, Mannheim, was appointed to the steering committee by the executive committee of the Deutsche Schmerzgesellschaft to represent the geriatrics subbranch. The Deutsche Gesellschaft für Schmerzmedizin was offered the opportunity to name a representative for the steering committee. The Deutsche Gesellschaft für Schmerzmedizin declined the offer (email of 14.02.2014) .
The tasks of the steering committee comprised definition of the key guideline questions and preparation of the recommendations for the consensus conferences. The members of the steering committee are listed in . Infobox 1.
Consensus committee
The executive committee of the Deutsche Schmerzgesellschaft decided to invite all specialist medical societies which represent an area of adult medicine covered by the"Weiterbildungsordnung" (WBO) regulations governing specialist training for physicians to participate. Further to this, all specialist societies that were involved with the first version of the guidelines were invited to participate, as was the Deutsche Gesellschaft für Schmerzmedizin. Professional associations were not invited to participate. With the exception of the Deutsche Gesellschaft für Dermatologie and der Deutsche Gesellschaft für Schmerzmedizin, all specialist societies that were approached accepted the invitation to participate. Three specialist societies did not wish to participate in the consensus conference or the Delphi procedure, but were willing to contribute their support. The Deutsche Gesellschaft für Psychologische Schmerzforschung undtherapie was invited to represent the specialist psychological societies. The participant specialist societies and their delegated members of the steering committee are listed in . Tab. 1
Patient support
Of the patient self-help organizations that were approached (Deutsche Rheuma-Liga, Deutsche Schmerzliga, Schmerz-LOS), only the Deutsche Schmerzliga declined the invitation to participate (email of 14.02.2014 SchmerzLOS was a member of the steering committee.
Editorial independence: approach to conflicts of interest Generation of the guidelines was financed by the Deutsche Schmerzgesellschaft and the participating societies. No direct or indirect commercial institution funding of any kind was used. The costs for development of the guidelines (programing the internet platform, literature acquisition costs, external moderation of the consensus conferences) were covered by the Deutsche Schmerzgesellschaft. The consensus conference travel costs were covered by the participants or their specialist societies. Travel expenses and other expenditures were billed according to the corresponding"Bundesdienstreisegesetz" (federal act governing business trips) or normal academic regulations. All members of the guidelines committee served on a voluntary basis and received no remuneration.
Stating of and approach to potential conflicts of interest
In addition to specialist expertise, the development of guidelines for medical care requires strict avoidance of commercial dependency, which could influence the guidelines. Participants' conflicts of interest statements are crucial for both the quality assessment of the guidelines and their public credibility. All participants involved in construction of the guidelines signed the Association of the Scientific Medical Societies in Germany (Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften, AWMF) statement covering potential conflicts of interest. The financial associations, other associations and conflicts of interests of steering and consensus committee members with third parties potentially having an interest in the guidelines are presented in . Tab. 2 and . Tab. 3.
The conflicts of interest specified by members of the steering committee were checked by two members of the Deutsche Schmerzgesellschaft executive board, neither of whom were involved in any other aspects of guideline development (Prof. Dr. med. Heinz-Raimund Casser, PD Dr. phil. Regine Klinger). Potential conflicts of interest arose due to the execution of studies on drug-based, physical or psychological therapeutic approaches to chronic pain, due to membership of psychotherapeutic schools and due to direction of or employment by clinical institutions in which patients receive treatment.
The specified conflicts of interest and their external evaluation were discussed by the steering committee in a personal meeting on 12.05.2014, in the presence of AWMF representative Dr. med. Monika Nothacker. The steering committee came to the conclusion that the group was balanced with respect to their interests (drug and psychological therapies, "school memberships").
The conflicts of interest specified by the consensus group were discussed at the consensus conference on 07.04.2014, in the presence of AWMF representative Dr. med. Nothacker Monika. The consensus group concluded that the group was balanced with respect to their interests.
Regulation of conflicts of interest in the sense of excluding individual participants from discussions or votes was deemed unnecessary, due to the use of formal techniques for the reduction of distortion risks (balanced group composition with plurality of interests, formal consensus process with independent external moderation and systematic review of the literature).
Methodology of guideline construction
The updating of the guidelines was performed in accordance with AWMF regulations [1] and the requirements of the German guideline evaluation instrument ("Deutsche Instrument zur methodischen Leitlinienbewertung" [2] ). Methodological guidance was provided by the director of the AWMF Institute for Medical Knowledge Management, Prof. Dr. med. Ina Kopp.
The time course of the entire development and consensus processes of the guidelines update is shown in . Tab. 4. Methods. The guidelines were developed by 25 scientific societies and two patient selfhelp organizations under the coordination of the Deutsche Schmerzgesellschaft (German Pain Society) and the Association of the Scientific Medical Societies in Germany ("Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften", AWMF). Results. A systematic literature search was performed in the CENTRAL, MEDLINE and Scopus databases from October 2008 to October 2013. Meta-analyses of randomized controlled trials (RCTs) of opioids in CNCP syndromes of study duration ≥4 weeks were conducted. Levels of evidence were assigned according to the Oxford Centre for Evidence-Based Medicine version 2009 classification system. The formulation and strength of recommendations was established in a multistep formalized consensus procedure, in accordance with AWMF rules and standards. The guidelines were reviewed by three scientific societies not involved in their development and were approved by the executive boards of the societies that were engaged in development of the guidelines. Conclusion. The guidelines will be published in several forms: complete and short scientific versions, as well as clinical practice and patient versions.
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Key questions
The following key questions were formulated by the steering committee in a Delphi procedure:
a. Key questions answerable by meta-analyses of randomized controlled clinical trials (RCTs) and RCT open-label extension studies
F For which chronic pain syndromes is there evidence for the efficacy of long-term therapy with opioid-containing analgesics? F How efficacious (pain reduction, improvement in physical function) are opioid-containing analgesics in longterm application? F How well tolerated (RCT dropout rate due to adverse effects) are opioid-containing analgesics in long-term application? F How safe (rate of serious adverse effects and mortalities) are opioid-containing analgesics in long-term application? F Are certain individual opioid-containing analgesics superior in terms of efficacy, tolerability and safety in particular chronic pain syndromes ("headto-head comparisons")? F Do different application forms (oral vs. transdermal) of opioid-containing analgesics differ in terms of efficacy, tolerability and safety in particular chronic pain syndromes ("head-tohead comparisons")? F Are opioid-containing analgesics superior to nonopioid analgesics in terms of efficacy, tolerability and safety in particular chronic pain syndromes ("head-to-head comparisons")? F By which procedures can patients who cannot be expected to experience long-term clinically relevant pain relief from opioid analgesics be identified early? F By which procedures can patients who can be expected to experience long-term clinically relevant pain relief from opioid analgesics be identified early? F After which treatment duration is a benefit and harm assessment advisable, as the rational basis for decisions F Which criteria are to be considered during the selection of drugs for longterm therapy of chronic pain?
Conflicts of interest of the delegates of the specialist societies (consensus committee)
Name
F In which clinical constellations can long-term application of opioid-containing analgesics be considered? F In which clinical constellations would long-term application of opioid-containing analgesics inadvisable? F In which clinical constellations is a specialist psychotherapeutic diagnostic assessment advisable in the context of long-term application of opioidcontaining analgesics? F Which diagnostic measures are recommended prior to commencing long-term application of opioid-containing analgesics? F What issues should treating physicians make patients aware of prior to commencing long-term application of opioid-containing analgesics? F Which criteria are to be considered during the selection of individual opioid-containing analgesics for longterm application? F How should opioid-containing analgesics for CNCP be titrated? F Which measures are recommended for the prophylaxis and treatment of adverse effects? F Is rescue medication rational in the context of long-term application of opioid-containing analgesics? F Is it rational to make attempts to reduce medication in the context of long-term application of opioid-containing analgesics? F Are "drug holidays" rational in the context of long-term application of opioid-containing analgesics? F In which clinical constellations is a long-term therapy with opioid-containing analgesics rational? F How should the efficacy and tolerability of long-term application of opioidcontaining analgesics be assessed and documented? F Which measures should be taken in response to an increase in pain in the context of long-term application of opioid-containing analgesics? F In which clinical constellations should long-term use of opioid-containing analgesics be terminated? F How can misuse (abuse) of opioidcontaining analgesics be recognized? F Which prophylactic measures are rational for avoiding misuse of opioidcontaining analgesics? F Which measures are rational in the context of misuse (abuse) of opioidcontaining analgesics? F Which particular elements (e.g. selection of the preparation, dosage, control examinations) are to be considered in the context of long-term use of opioid-containing analgesics by special patient groups (children, adolescents, pregnant women, elderly patients, patients with current medication misuse behavior/medication dependency)?
Literature search for guidelines
A systematic review of guidelines for the treatment of chronic pain with opioidcontaining analgesics (literature searched up until July 2013), with methodological evaluation using the AGREE instrument was used [20] . Several recommendations and the concept of practical tools were adopted from the guidelines that were judged have the highest methodical quality, the Canadian practice guidelines [8] .
Literature search for randomized controlled studies
Databases and search strategy. The search strategy is orientated to the current Cochrane reviews [5, 18] and the publication of a protocol for the systematic review of RCTs of opioid-containing analgesics in CNCP [4] . and a systematic review [9] . The search results were then supplemented as appropriate. The selected studies were presented to the members of the steering committee. Studies that were considered relevant by the steering committee, but which had not been found by the search, were supplemented. For the systematic reviews and guideline recommendations, the literature of the first version of the guidelines (systematic literature search in MEDLINE and CENTRAL from 1/1990 until 09/2008 [23] ) was considered. If data (e.g. means, standard deviations, study protocol) from the RCTs included in the meta-analyses were not reported in the original publication, it was checked whether these data were reported in www.clinicaltrials.gov.
Archiving. The search strategies were stored electronically. The results of the search strategies were saved. The full-texts of all studies that were used in the recommendations of the working groups were made available to all participants of guideline development on a password-protected noncommercial Internet platform.
Selection of evidence
Inclusion and exclusion criteria. On the basis of titles and abstracts, and under the application of defined inclusion and exclusion criteria (filters), the search results were analyzed for their suitability for the RCT meta-analysis by PD Dr. Winfried Häuser and Dr. med. Patrick Welsch. Filter 1 was used to apply the following exclusion criteria: question not investigated; not a controlled study; animal model-based study; not a full-text publication (e.g. abstract only); case study; letter to the editor; double publication. The full texts of the remaining studies were ordered. Filter 2 was defined by "inclusion and exclusion on the grounds of filter 1 criteria after reading the full text".
Study design. The inclusion and exclusion criteria named in the following are valid for the conducted meta-analyses of placebo-controlled studies. We included RCTs with a therapeutic goal (pain reduction). Included studies had to have been published in a peerreviewed journal. Studies that were only published as abstracts or posters were excluded.
We included studies with parallel, cross-over and enriched enrolment randomized withdrawal (EERW) designs. In an EERW design study, the first phase of the study is carried out without blinding of patients and study physicians. In the second, double-blind phase, only those patients showing a response-a response being defined by predefined criteria, e.g. 50% pain reduction-and not declining further use of the preparation due to ad- Expert opinion without critical analysis or based on physiological or experimental research or "basic principles"
Expert opinion without critical analysis or based on physiological or experimental research or "basic principles"
RCT randomized controlled trialUsers can use a minus sign "−" to indicate the degree that is lacking in order to be able to come to a definitive answer because: a. EITHER a single result with a wide confidence interval (e.g. an ARR is not significant in one RCT, but the confidence interval cannot exclude clinically relevant adverse effects and usage); b. OR a systematic review with worrying (and statistically significant) heterogeneity is included. Such evidence is nonuniform and can thus only generate a level d recommendation. a With homogeneity we mean a systematic review without meaningful variance (heterogeneity) between individual studies with respect to the direction and variance of the results. Not all systematic reviews with statistically significant heterogeneity must necessarily be worrying and not all worrying heterogeneity has to be statistically significant. As mentioned above, studies with worrying heterogeneity should be denoted by a "-" at the end of the desired level. b " Clinical decision rule" (CDR). These are algorithms or points systems which lead to a prognostic estimation or a diagnostic category. c See note #2 as an aid to comprehension, grouping and use of studies with wide confidence intervals. d Applies if all patients died before the therapy was available and after the introduction of the therapy, some patients survive; or when some patients died before the therapy was available and after the introduction of the therapy, no patients died. e By qualitatively poor cohort studies, we mean those which have not clearly defined the comparison group and/or exposure and results are not measured in the same objective way (blinded) in both groups (exposed and nonexposed) and/or no appropriate confounding factors were identified and controlled and/or had inadequate follow-up rates.By qualitatively poor case-control studies, we mean those without a clearly defined comparison group and/or exposure and results are not measured in the same objective way (blinded) in both groups (exposed and nonexposed) and/or no appropriate confounding factors were identified and controlled. f Validation in part of the control sample arises when all information is gathered in one branch and this information is then artificially separated into derivation and validation groups. g An "absolute SpPin" is a diagnostic outcome, the specificity of which is so high, that a positive outcome includes the diagnosis. An "absolute SnNout" is a diagnostic outcome, the sensitivity of which is so high, that a negative outcome excludes (out) the diagnosis. h Good reference standards are independent of the test and applied to all patients in a blinded or objective way. Poor reference standards are applied randomly, but are, however, independent of the test. The use of nonindependent reference standards (if the test is included in the reference or if the test influences the reference) implies a level 4 study. i Validation studies test the quality of a specific diagnostic test based on the previously developed evidence. An explorative study gathers information and investigates all data (e.g. using a regression analysis), in order to find out which factors are significant. j By qualitatively poor prognostic cohort studies, we mean those in which the control sample is distorted and those patients who already have that outcome are preferred or measurement of the results is not carried out in <80% of the study population or the result is not measured in a blinded, objective way or when confounding factors were not controlled for. k A good follow-up rate in a differential diagnosis study is >80%, with appropriate time for the occurrence of alternative diagnoses (e.g. 1-6 months acute, 1-5 years chronic).
verse effects, are accepted. One proportion of the responders continue to receive the study drug; another proportion receive placebo. The RCT is thus conducted exclusively in responders. In light of this selection, the applicability of the results of such studies to the total population of patients with the disease in question has to be viewed critically. Nonetheless, the EERW approach is considered to represent an appropriate design for studies in chronic pain [8, 17] . For the assessment of the efficacy of an analgesic substance in the context of longer-term use, this selection process in fact mirrors the situation in clinical practice (ecological validity). Studies with a cross-over design were only included if (a), separated data from the two periods were reported or (b), statistical tests were performed which excluded statistically significant carry-over effects or (c), statistical adjustments were carried out in the case of a significant carry-over effect. For the purposes of quantitative data synthesis, studies with a parallel or cross-over design and studies with an EERW design were analyzed separately. This is because the patient population of the EERW design double-blind phase differs from the patient population of a parallel or cross-over design study, due to the selection in the first phase. This is linked to the fact that the tolerability of a drug is more favorably judged by an EERW study design than by studies with a parallel or cross-over design
We excluded studies in which, following an unblinded start phase, the opioidcontaining analgesic was completely tapered out and a parallel double-blinded placebo controlled study was then performed with the responders of the unblinded start phase.
We excluded studies in which the primary aim was to assess the efficacy of opioid-containing analgesics as rescue medication.
We excluded studies with an experimental design, e.g. where the study was primarily conducted to study pain mechanisms and was not focused on therapeutic purposes (pain reduction) Duration of the therapeutic phase was required to be at least 4 weeks (titration and maintenance phase in the case of par-allel and cross-over design; double-blind withdrawal phase for EERW design).
Participants. Number of patients: studies should include at least 10 patients per treatment arm.
Studies should be carried out with patients (male and female) of all age groups and ethnicities with chronic (lasting at least 3 months) noncancer pain.
Interventions.
We considered trials which compared opioid-containing analgesics to placebo, a non-opioid-containing analgesic, another opioid-containing analgesic or a nonpharmacological intervention. We analyzed studies with drugs given by oral or transdermal application. Studies with other application routes (e.g. intrathecal) were excluded.
We included studies in which the opioid-containing analgesic was combined with abuse deterrent formulations (ADF; e.g. naloxone).
We included studies with tramadol, a μ-opioid receptor agonist and norepinephrine and serotonin uptake inhibitor. We included studies with tapentadol, a μ-opioid receptor agonist and norepinephrine uptake inhibitor.
From the quantitative data synthesis, we excluded studies in which the opioidcontaining analgesic was combined with a nonopioid analgesic in a fixed ratio (socalled combined preparations). We excluded studies in which an opioid-containing analgesic not in an ADF was compared to the same opioid-containing analgesic in an ADF (e.g. oxycodone with naloxone), or studies in which a combination of two opioid-containing analgesics was compared to a single opioid-containing analgesic.
We excluded studies with propoxyphene because the drug has been withdrawn from the market (US Food and Drug Agency news release from 19.11.2010 ). . 6, [21] ).
Evaluation of the evidence
Within the context of an evidence hierarchy, meta-analyses and systematic reviews of double-blinded RCTs repre-sent the highest level of evidence in these guidelines for therapeutic procedures. This is because the results of such studies have the lowest risk of bias.
Quality of evidence criteria. The quality of the evidence was defined according to the Cochrane Risk of Bias Table [13] and Grading of Recommendations Assessment, Development and Evaluation (GRADE; [3] ). The operationalization of the GRADE criteria was orientated to current Cochrane reviews ( [5, 18] , see .
Infobox 2).
GRADE distinguishes between the following categories of evidence quality [3] : F High quality (++++): we are very confident that the true effect lies close to that of the estimate of the effect. F Moderate quality (+++): we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. F Low quality (++): our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. F Very low quality (+): we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect; any estimate of effect is very uncertain.
Compilation of meta-analyses and evidence tables
Together with several members of the steering committee, as well as physicians and psychologists not belonging to the steering committee, the steering committee spokesman carried out meta-analyses for all types of CNCP, for which at least one RCT of at least 4 weeks duration was identified [15, 22, 24, 27, 28] . Additionally, a meta-analysis of open-label extension studies lasting ≥26 weeks was performed [12] . The following outcome measures for efficacy and risks were selected [19] :
Efficacy (patient-reported outcomes). 
Randomization (systematic selection bias)
There is a low risk of selection bias if the investigators describe the method of random allocation of patients into the therapy and control groups by the one of the following methods: referral to a random number table, use of computer-generated random numbers, coin tossing, shuffling cards or envelopes, dice throwing or drawing lots. There is a high risk of selection bias if the allocation is generated in terms of odd or even numbers in the date of birth, date of hospital admission or hospital record number, as well as in the case of allocation by judgment of the physician, the patient's wishes, results of a laboratory test or availability of the intervention.
Allocation concealment (selection bias)
There is a low risk of systematic selection bias if the participants and investigators could not foresee allocations because one of the following methods, or an equivalent method, was used to conceal the allocation: central allocation (e.g. telephone, internet or pharmacy-controlled random allocation; sequentially numbered drug containers of identical appearance or sequentially numbered sealed opaque envelopes).
There is a high risk of systematic selection bias if participants and investigators could possibly foresee allocations, for example due to the use of an openly available treatment plan (e.g. a list with randomly generated numbers); assignment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed, nonopaque or not sequentially numbered); alternating or rotating treatment group allocation; date of birth; case record number or other explicitly unconcealed allocation procedures.
Blinding of participants and personnel/treatment providers (systematic performance bias)
There is a low risk of performance bias if blinding of participants was ensured and it was unlikely that the blinding could have been lacking or incomplete; or if blinding was lacking or incomplete, the review authors judge that the outcome was not influenced by the lack of blinding. There is a high risk of performance bias if blinding of participants was not ensured.
Blinding of outcome assessor (systematic detection bias)
There is low risk of systematic detection bias if the outcome assessor assessing patient-reported outcomes is not the clinical investigator, but rather a statistician not involved in the treatment of the patient. There is an unclear risk of systematic detection bias if no details on the identity of the outcome assessor are reported. There is a high risk of systematic detection bias if the outcome assessor was involved in treatment of the patients.
Incomplete outcome data (systematic attrition bias due to loss of participants)
There is low risk of systematic bias if all randomized patients were reported or analyzed in the group to which they were allocated by randomization and dropouts were analyzed by the baseline observation carried forward (BOCF) method (baseline measurements used for data analysis). There is an unclear risk of systematic bias if all randomized patients were reported or analyzed in the group to which they were allocated by randomization, and dropouts were analyzed by the last observation carried forward (LOCF) method (last measurements used for data analysis). There is a high risk of systematic bias if no intention-to treat (ITT) analysis was carried out (analysis technique in which patients are analyzed according to their original group assignment, regardless of whether they received the intended therapy completely, in part or not at all) or only study completers were evaluated.
Selective reporting (systematic reporting bias)
There is low risk of reporting bias if the study protocol is available and all of the study's prespecified primary and secondary endpoints that are of interest to the review have been reported in the prespecified way; or if the study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were prespecified (a convincing text of this nature is probably uncommon).
There is a high risk of systematic reporting bias if not all of the study's prespecified primary outcomes have been reported; one or more primary outcomes are reported using measurements or analysis methods that were not prespecified; one or more of the reported primary outcomes were not prespecified (independently of whether justification for use of an unexpected result is provided); one or more outcomes that are of interest to the review are reported incompletely, such that they cannot be entered into meta-analysis; the study report fails to include results for a key outcome which would be expected in a study of this nature.
Group similarity at baseline (systematic selection bias)
There is low risk of bias if groups are similar at baseline for demographic factors, values of main outcome measures and important prognostic factors. There is high risk of bias if groups are not similar at baseline for demographic factors, values of main outcome measures and important prognostic factors.
Other bias (systematic funding bias)
We assumed a low risk of systematic bias if the study was initiated by the investigator and the study was not funded by a pharmaceutical company. We assumed a high risk of systematic bias if the study was funded by a pharmaceutical company. We extracted the following information regarding relationships to the pharmaceutical industry: author affiliations with the pharmaceutical industry, funding of study by the pharmaceutical industry, the pharmaceutical industry provided the study drug or statistical analysis was performed by an industry-affiliated statistician. In the instance of any of these constellations, we concluded that there was a high risk of systematic bias.
(RD) for dichotomous data and standardized mean differences (SMD) for continuous data, which were calculated using a random effects model (method of inverse variance). We expressed uncertainty using 95% CIs. For dichotomous variables, the threshold for "appreciable benefit" or "appreciable harm" was set at a relative risk reduction (RRR) or relative risk increase (RRI) ≥10% [5] . We used Cohen's categories to evaluate the magnitude of the effect size, calculated by SMD, with Hedges' g of 0.2= small, 0.5= moderate and 0.8= large [6] . We labelled g <0.2 to be a "not substantial" effect size. We assumed a "minimally important difference" if Hedges' g was ≥0.2 [7] . The heterogeneity of the pooled data effect estimates was described using the I 2 statistic; I 2 >50 was defined as indicating high heterogeneity [13] . The tables of evidence outlining study characteristics (type and dosage of therapy, duration of therapy and follow-up, number of patients in the experimental and control groups, inclusion and exclusion criteria, methodological quality) are available as supplementary material accompanying the systematic reviews and meta-analyses that were conducted for the construction of the updated guidelines [12, 15, 22, 24, 26, 28] .
The systematic reviews underwent an anonymous expert reviewal process by the journal Der Schmerz. No member of the expert review panel was a member of the steering or the consensus committee (personal communication from the editorial office).
Formulation of the recommendations
Awarding grades of recommendations. The recommendations were graduated (strength of the recommendation) according to AWMF regulations [1] . The recommendations are based on the identified evidence, clinical experience and patient preferences, and thus incorporate explicitly subjectively evaluated elements. In the case of S3 guidelines, the formal process of reaching a consensus on the adoption of the recommendations includes consideration of the methodically prepared evidence from a clinical perspective and discussion of the recommendations upon this basis. Subsequently, the strength of the recommendations is set and the recommendations are graded. In addition to consideration of the underlying evidence, the following criteria should be directly addressed during the discussion and setting of recommendation grades: F Consistency of the study results F Clinical relevance of endpoints and effect sizes F Risk-benefit ratio F Ethical, legal, economic considerations F Patient preferences F Adaptability to the target patient group and the German health care system F Feasibility in everyday life/in different areas of care (. Fig. 1) The strengths of the recommendations were formulated according to AWMF regulations [1] (. Tab. 7).
Criterial for raising or lowering the grade of a recommendation. Levels of evidence (according to Oxford) determine the derivation of recommendation grades: the higher the level of evidence, the stronger the recommendation. Generally, recommendation grade A (strong recommendation) corresponds to level I evidence, recommendation grade B (recommendation) to level II evidence and an open recommendation to levels III, IV and V evidence (. Fig. 1 ).
In addition evidence levels and ethical obligations, the process of awarding grades of recommendations also considers the clinical relevance of the effectiveness of the studies, the applicability of study results to the target patient group, patients' preferences and the feasibility of the treatment within the health care system. According to these consensus aspects, the grade of a recommendation may be raised or lowered (. Fig. 1) . The process of awarding grades of recommendations involves both explicit and implicit evaluation elements, and proceeds within the context of a multistep consensus procedure (nominal group procedure via Delphi procdure within the steering committee; online vote by the steering and consensus committee and consensus committee consensus conference). In order to make intended changes in grades of recommendations (raising/lowering) transparent, potential criteria for raising or lowering the grade of a recommendation were defined a priori by the steering committee in a Delphi procedure:
Raising the grade of a recommendation for an intervention F by one degree: patients' preferences or ethical obligations (patient charter and physicians' code of conduct) F by two degrees: patients' preferences or ethical obligations
Lowering the grade of a recommendation for an intervention F by one degree: no RCTs (placebo and/ or nonopioid analgesic) ≥12 weeks or number of patients in meta-analyses <400 and/or only one RCT [19] or inferior risk-benefit ratio compared to other drug-based or non-drugbased therapy alternatives F by two degrees: two of the three criteria above F by three degrees: all of the three criteria above A further recommendation category-the clinical consensus point (CCP)-was adopted from the national care guidelines, meaning that in a situation where experimental research is not possible or not desirable, a recommendation as good clinical practice arrived at by consensus and a recommendation as a standard of treatment on the basis of the clinical experience of the guidelines committee [10] . Health economics aspects were not explicitly considered during establishment of the recommendations.
After a consensus on the recommendations had been reached, the steering committee drew up a full-text draft, identified key recommendations, formulated quality objectives and produced a short version. The final vote was taken by the steering committee in a Delphi procedure.
Classification of the strength of the consensus
Since the steering committee members' knowledge of the literature predicted that some of the issues addressed by the guidelines would not be answerable on the basis of studies and that controversial opinions were possible in the case of several topics, it was decided that-in addition to evidence levels and recommendation grades-the strength of consensus should also be given for the individual recommendations [14] . Stating the strength of the consensus for each recommendation provides guideline users with an impression of the extent of the members' vote [14] . The strength of the consensus was classified as follows [14] : F Strong consensus: approval from >95% of participants F Consensus: approval from 75-95% of participants F Majority approval: approval from 50-75% of participants F No consensus: approval from <50% of participants F A minority vote, with reason, was possible.
The steering committee templates for the recommendations were adopted at the rounds of the Delphi procedure by a simple majority. The steering committee spokesman (PD Dr. med. Winfried Häuser) was not entitled to vote in the Delphi procedure rounds.
In the online vote, each participating specialist society and patient organization had one vote. All representatives of specialist societies and patient organizations participated in the online vote. During calculation of the strength of the consensus, abstentions were counted as "no" votes. At the consensus conference, only the recommendations that had reached an agreement of >95% were revoted on.
In order to have a comprehensible basis for the allocation of votes at the consensus conference, the executive committee of the Deutsche Schmerzgesellschaft decided that there be one vote per section of the model ordinances for regulations ("Musterweiterbildungsordnung", WBO) governing physicians, i.e., specialist societies belonging to the same section of the WBO were required to reach agreement on their vote. Die DGPSF was allocated one vote. Both self-help organizations were allocated one vote each at the consensus conference. In the case of a lack of consensus between societies that had to share a vote, this was judged as abstention. A total of 20 representatives of specialist societies and patient organizations participated in the consensus conference. These 20 representatives had 14 votes at their disposal (12 votes for sections of the WBO model ordinances; one vote each for specialist psychological societies and patient representatives). Four specialist society representatives (three of whom were representatives of sections of the WBO model ordinances) were absent with excusals. The three absent representatives of sections of the WBO model ordinances had conveyed their decisions on how they wished to use their votes. The Deutsche Ophthalmologische Gesellschaft abstained to vote on any of the recommendations. The Deutsche Gesellschaft für Urologie approved all recommendations in the online vote. The votes of the Deutsche Gesellschaft für Neurochirurgie in the online vote were available. In the case of recommendations to which no changes in content were made during the consensus conference, the available votes of the three absent specialist societies were entered into the calculation of the strength of the consensus. In the case of recommendations to which changes in content were made during the consensus conference, the votes of the three absent specialist societies representing sections of the WBO model ordinances were not counted in the calculation of the strength of the consensus. Abstentions from specialist societies present at the consensus conference not entered into the calculation of the strength of the consensus, i.e., only "yes" and "no" votes were considered. The Deutsche Schmerzgesellschaft was entitled to participate in the online vote, but had no entitlement to vote at the consensus conference..
Results
Rounds of the Delphi procedure and the consensus conferences
For reasons of time-efficiency, suggestions for recommendations were generated by the steering committee spokesman, and subjected to modification and consensus reaching (with majority approval) by the steering committee in 20 rounds of a Delphi procedure (via email 
External review and adoption of guidelines
The final manuscript was sent to the boards of directors of the participating specialist societies, with the request that they offer their opinions on and authorize the manuscript. With the exception of the Deutsche Gesellschaft für Osteologie, the boards of directors of all participating specialist societies have approved the guidelines. The Deutsche Gesellschaft für Osteologie has declined to comment until the issue of liability for the content of the LONTS has been clarified. The external review was carried out by the Drug Commission of the German Medical Association (Arzneimittelkommission der Deutschen Ärzteschaft), the Swiss Society for the Study of Pain (Schweizer Gesellschaft zum Studium des Schmer zes) and the Austrian Pain Society (Österreichische Schmerzgesellschaft). The German Pain Association (Deutsche Gesellschaft für Schmerzmedizin) was asked for a review. The Deutsche Gesellschaft für Schmerzmedizin did not accept the offer (letter of 16.06.2014). Formal requests for changes to the text of the guidelines from reviewers and the specialist societies were considered.
The phase of guideline development during which the guidelines were open to public comment was publicized in the media by the offices of the Deutsche Schmerzgesellschaft and took place between 14.07.2014 and 30.08.2014. The relevance of the public comments was assessed by the steering committee in a Del-phi procedure. On the basis of the public comments, one recommendation was added to the guidelines by a steering and consensus committee Delphi procedure. In a steering committee Delphi procedure, four comments were expanded upon.
Formal request from the reviewers for changes to the text of the guidelines were taken into account. The comments from the specialist societies and reviewers, as well as those of the public comment period, are published on the AWMF website as an appendix to the methods report of guideline development (http://www. awmf.org/uploads/tx_szleitlinien/145-003m_S3_LONTS_2014-09.pdf).
A pocket version of the guidelines will be developed in autumn 2014 in collaboration with the DEGAM.
The patient guidelines were developed in collaboration with both delegates of the patients self-help organizations participating in guideline development and the German Agency for Quality in Medicine (Ärztlichen Zentrum für Qualität in der Medizin, ÄZQ; Frau Corinna Schäfer, M. A.). A pilot version of the patient guidelines was distributed at a meeting of the SchmerzLOS self-help group. Upon offering feedback back, the eight persons present at the meeting (seven female, one male) reported that the text was comprehensible to the layman and that the most important patient-relevant questions were answered.
Approval by the AWMF
The guideline update was submitted to the AWMF on 15.09.2014 and approved by the AWMF on 30.09.2014 (AWMF registration number 145/003).
Discussion
Applicability and comprehensibility
Due to the paucity of data, health economic aspects have not been dealt with comprehensively. Costs were not explicitly considered.
The considered issues were thematically grouped and addressed in the chapters of the guidelines publication. The guidelines are followed by commentaries, in which explanations-including the liter-ature sources providing the evidence basis-for the guidelines can be found. The tables of evidence (content, methodological quality and external validation of the studies) and the quantitative data syntheses (meta-analyses) with their corresponding Forest plots are freely available on the AWMF homepage, as well as in PubMed as Electronic Supplementary Material to the conducted meta-analyses [12, 15, 22, 24, 26, 28] .
Dissemination and implementation
The guidelines (short and full-text versions), the methods report and the evidence report are viewable on the AWMF internet pages (http://www.awmf.org/ leitlinien/detail/ll/145-003.html).
The complete scientific version of the guidelines is presented in this special issue. A short version of the guidelines was published in the Deutsche Ärzteblatt in October 2014 (http://www.aerzteblatt.de/ archiv/162926/Langzeitanwendung-von-Opioiden-bei-nichttumorbedingten-Schmerzen).
The patient versions of the guidelines (short and long versions) will be available on the homepages of the self-help organizations (http://www.schmerzlos-ev.de; http://www.rheuma-liga.de). The content of the new guidelines is presented in member magazines of both self-help organizations. In October 2014-based on the update of the scientific and patient LONTS-the ÄZQ developed patient information entitled "Opioide bei chronischen Schmerzen" ("Opioids in Chronic Pain"; http://www.patienten-information. de/mdb/downloads/kip/aezq-versionkip-opioide-bei-chronischen-schmerzen. pdf).
The recommendations contained within the guidelines were presented in a primary symposium at the German Pain Congress, October 2014 in Hamburg. The members of the guidelines committee will present the guideline recommendations at regional training events and quality circles.
The following measures are planned for international circulation of the guidelines: All articles contained in the special issue of Der Schmerz devoted to the guidelines are available in English as "open-ac-cess" publications in PubMed. An English translation of the short version of the guidelines will be available in Dtsch Ärztebl Int. The guidelines will be available on the Guidelines International Network homepage at: http://www.g-i-n.net.
Evaluation of the guidelines
Implementation of these guidelines should improve the quality of treatment. Since guidelines are formally considered as a thesis, it should as such be evaluated-after an appropriate amount of time-whether these objectives are being realized. The following measures are planned for evaluation: a) Analysis of Barmer Ersatzkasse (German health insurance provider) data to ascertain whether the frequency of guideline-nonconformal prescriptions of opioid-containing analgesics for functional/somatoform disorders [11, 16, 25] has decreased. b) Areas not addressed by the guidelines and perceived barriers should be discussed within the context of audits by participants of the guidelines committee at local quality circles (pain therapy) and inpatients institutions (pain therapy), and common strategies for improved guideline implementation should be developed.
Methodological differences to the first version of the guidelines
The steering committee also included representatives from the fields of general medicine, geriatrics and psychosomatic medicine. The formulation of the guidelines was arrived at interactively, by numerous rounds of a steering committee Delphi procedure. All sections of the WBO model ordinances pertaining to adult patients were involved in the consensus committee. The consensus conferences were moderated by an AWMF representative. The strength of the recommendations was calculated. Specialist societies carried out the external review. "Long-term application" of opioids was defined. The inclusion and exclusion criteria of the RCTs were analyzed. In addition to pain, other measures of efficacy and measures of the extents of risks were included in the quantitative data syntheses. The evaluation of the efficacy of opioid-containing analgesics in comparison to other analgesics was achieved by means of a meta-analysis of direct comparisons, and no longer by means of separated meta-analyses of RCTs with opioid-containing analgesics and of RCTs with non-opioid-containing analgesics in CNCP syndromes. For the evaluation of long-term efficacy and risks, a meta-analysis of "open-label extension studies" ≥26 weeks of RCTs was conducted. For the evaluation of long-term risks, cohort studies were also considered.
The quality of the evidence was rated according to GRADE, rather than according to SIGN (Scottish Intercollegiate Guidelines Network). No longer were any RCTs excluded from the guideline recommendations on the basis of poor methodological quality. The graduation of the strength of recommendations and the formulation of the recommendations was in accordance with AWMF regulations, rather than according to SIGN. A priori definition of criteria for raising or lowering a level of evidence and raising or lowering a grade (strength) of a recommendation was opted for, in order to make decisions taken in the consensus process transparent and minimize the influence of individual opinions during the consensus conferences.
Differences to the content of first version of the guidelines
The following recommendations were not renewed: a) Long-term therapy with opioid-containing analgesics should only be administered in cases where other drugbased and non-drug-based therapeutic measures have failed. Possible indications and contraindications (symptomatic presentations with ICD-10) for a therapy with opioid-containing analgesics were named. Recommendations were made for special patient groups (e.g. children, pregnant women).
Limitations of evidence-based medicine
The extraction of data from the studies was limited by the following factors: In many studies, the techniques used for randomization, allocation to treatment groups and blinding of the assessor were not described. We did not contact the authors of the studies to request the unreported details. Therefore, it is possible that the actual methodological quality of the study was higher than the reported methodological quality of the study.
In many studies, inclusion and exclusion criteria were not precisely defined. The extensive inclusion and exclusion criteria of most studies limit the representativeness of the RCT for patients in routine clinical care considerably, since many studies excluded patients with advanced age (>75 years), patients with relevant physical diseases (heart, liver, kidneys) and patients with severe psychological disorders.
In order to clarify the question of the long-term efficacy (>12 weeks) of opioidcontaining analgesics, a proportion of the steering committee is of the opinion that randomized controlled (placebo, other active measure) studies with a duration of 26-52 weeks should be performed. A proportion of the steering committee is of the opinion that such studies cannot be performed due to ethical and organizational reasons.
Barriers to implementation of the guidelines and possible solutions
Potential barriers to the application of the guideline recommendations can be identified among patients, their relatives and persons of the health care system, as well as in the media:
Patients: ignorance (e.g. of potential adverse effects of the therapy); unrealistic therapeutic expectations or irrational fear of long-term therapy with opioid-containing analgesics Relatives: ignorance (e.g. of potential adverse effects of the therapy); unrealistic therapeutic expectations or irrational fear of long-term therapy with opioid-containing analgesics
Persons of the health care system (physicians, psychologists, physiotherapists): ignorance (e.g. of potential adverse effects of the therapy); emotional reservation concerning opioid-containing analgesics; increased time expenditure associated with issuing prescriptions for narcotic substances; unrealistic therapeutic expectations or complete refusal of longterm therapy with opioid-containing analgesics; perception of the guideline recommendations as an intrusion on medical therapeutic freedom and as "cookbook medicine".
Media: promotion of inappropriately high therapeutic expectations or irrational fear of long-term therapy with opioidcontaining analgesics Possible solutions to these problems are effective circulation and implementation of the guidelines, as well as balanced reports in the media following consultation with medical experts.
Validity and updating procedures
The guidelines are valid until 10/2019, at which point an update is planned. Any knowledge amassed in the meantime that could necessitate an update of individual sections or recommendations will be monitored by the steering committee. Relevant abstracts of all new publications on therapy with opioid-containing analgesics in CNCP appearing in MEDLINE will be checked for their relevance to the guidelines by the guideline secretary.
Leads from the addressees of the guidelines are also strongly encouraged and can be communicated directly to the coordinator (whaeuser@klinikum-saarbruecken.de) or via the comment function on the AWMF homepage. In the case of new, relevant and recognized knowledge that contradicts the statements made by the guidelines, it is intended that, within 3 months, reports of this fact will appear in the specialist publications of the participating societies and an addendum to the guidelines will be issued on the AWMF homepage.
The date of publication, the date of the next planned update, reports of planned updates/those required in the meantime will be indicated on publically accessible pages of the AWMF internet site (http:// www.awmf-leitlinien.de). Only the most recent version of the guidelines in the AWMF registry is valid.
